SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 15, 2010

NEOSTEM, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware	0-10909	22-2343568
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

420 Lexington Avenue, Suite 450, New York, New York 10170
(Address of Principal Executive Offices)(Zip Code)

(212) 584-4180
Registrant's Telephone Number

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

Beginning on March 15, 2010 at an investor presentation by the Company, and from time to time thereafter, the Company intends to present and/or distribute to the investment community a slide presentation. The slide presentation is attached hereto as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 to the Current Report on Form 8-K, the information contained in this Current Report on Form 8-K, including without limitation, the information contained in Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Forward Looking Statements

This Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically are identified by use of terms such as "may," "will," "should," "plan," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. Forward-looking statements represent the Company's management's judgment regarding future events. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. All statements other than statements of historical fact included in this Current Report on Form 8-K are forward-looking statements. The Company cannot guarantee the accuracy of the forward-looking statements, and you should be aware that the Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including the statements under "Risk Factors" contained in the Company's reports filed with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Slide Presentation, dated March 15, 2010 (Exhibit 99.1 is furnished as part of this Current Report on Form 8-K).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, NeoStem has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOSTEM, INC.

Date: March 15, 2010

By: /s/ Catherine M. Vaczy
Name: Catherine M. Vaczy
Title: Vice President and General Counsel

NEOSTEM, INC. ("NBS")

Investor Presentation

March 2010

NeoStem

YOUR CELLS • YOUR USE • YOUR LIFE

WWW.NEOSTEM.COM

Forward-Looking Statements

Included in this presentation are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from anticipated results, performance or achievements expressed or implied by such forward-looking statements. When used in this prospectus, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "plan," "intend," "may," "will," "expect," "believe," "could," "anticipate," "estimate," or "continue" or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements. Additionally, statements concerning our ability to successfully develop the adult stem cell business at home and abroad, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the role of VSEL™ Technology in that future, and the potential revenue growth of such business are forward-looking statements. Our future operating results are dependent upon many factors, and our further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. Forward-looking statements may not be realized due to a variety of factors, including, without limitation, (i) our ability to manage the business despite continuing operating losses and cash outflows; (ii) our ability to obtain sufficient capital or a strategic business arrangement to fund its operations and expansion plans, including meeting its financial obligations under various licensing and other strategic arrangements and the successful commercialization of the relevant technology; (iii) our ability to build the management and human resources and infrastructure necessary to support the growth of the business; (iv) competitive factors and developments beyond our control; (v) scientific and medical developments beyond our control; (vi) our inability to obtain appropriate governmental licenses or any other adverse effect or limitations caused by government regulation of the business; (vii) whether any of our current or future patent applications result in issued patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business; (viii) whether any potential strategic benefits of various licensing transactions will be realized and whether any potential benefits from the acquisition of these new licensed technologies will be realized; (ix) whether we can obtain the consents we may require to sublicensing arrangements from technology licensors in connection with technology development; (x) factors regarding our business in China and, generally, regarding doing business in China, including through our variable interest entity structure and other factors disclosed in the Company's prospectus on Form 424B1 filed with the SEC on February 12, 2010; and (xi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings".

All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. We undertake no obligation to update or revise these forward-looking statements, whether to reflect events or circumstances after the date initially filed or published, to reflect the occurrence of unanticipated events or otherwise, except to the extent required by federal securities laws.

Company Overview

Summary Profile	
Ticker	NBS (AMEX)
2010 Trading Range	$1.26 - $2.15
Market Cap [1]	$68.7 million
Corporate Headquarters	NYC
Subsidiary (location)	Suzhou Erye (China) – pharmaceuticals

[1] *Based on 42.9 million shares outstanding and $1.40 closing price on 3/12/10.*

Investment Summary

- **Adult stem cell platforms offer high margin, near and long-term revenue opportunities**
  - 2010 launches – orthopedic and anti-aging therapies in PRC; cosmetic and anti-aging therapies in Taiwan
  - Future – innovative VSEL™ technology therapies for cardiovascular, stroke, wound healing
- **Majority ownership interest in profitable and growing pharma business**
  - Estimated >$60 million in revenues for full year 2009
  - 7 new products in pipeline and several others under in-licensing negotiation
  - Benefit from $124 billion China healthcare spending initiative
- **Partnerships/collaborations in China to accelerate development & launch timelines**
  - Favorable regulatory and commercial landscape in China
- **Strong management team, advisors and board with significant U.S. and China experience**

Key Company Milestones

2006 - 2008

- √ Appointed Dr. Robin Smith as CEO (2006)
- √ Purchased NeoStem assets (2006)
- √ Acquired world-wide VSEL™ technology license (2007)
- √ Received DoD earmark – adult stem cell therapy for wound healing (2008)
- √ Raised ~ $16 million

2009 – 2010 to-date

- √ Commenced operations in China
- √ In-licensed stem cell applications for cosmetic, orthopedic, wound healing
- √ Partnered with Enhance Biomedical – treatment network in PRC and Taiwan for stem cell therapeutics
- √ Acquired 51% stake in Suzhou Erye
- √ VSEL™ technology data reported at ASH
- √ NIH Grant & University of Michigan sponsored research agreement – stem cells for bone defects
- √ Received QETC certification from NYS for 2010
- √ Co-inventor of VSEL™ technology Dr. Mariusz Ratajczak joins Scientific Advisory Board
- √ Raised ~ $23 million

As of May 2006 Market Cap: $6M	As of March 2010 Market Cap: $69M

Adult Stem Cell Initiatives
U.S. & China

Stem Cell Market Opportunity

Attractive market with both near- and longer-term opportunities

- **Fragmented market with significant barriers to entry**
- **Commercial opportunities already being realized ex-U.S.**
  - Expedited clinical and regulatory pathways compared to U.S.
  - Regulated by the Ministry of Health in China
- **Foundation for future market growth in the U.S.**
  - 40+ years treatment for cancer and anemia through bone marrow transplants
  - 2,700+ stem cell clinical trials ongoing *(www.clinicaltrials.gov)*
  - 16+ stem cell products expected to be approved by FDA, resulting in 1.9 million annual procedures, by 2017 *(RRY Publications)*
- **Global stem cell product market expected to reach $88 billion by 2014** *(Markets and Markets)*

Leading U.S. Stem Cell Operations

Adult stem cell banking

- **Recurring revenue stream**
- **Minimally invasive procedure ("apheresis")**
- **Growing network in major metropolitan areas**
  - Expand to ten centers by end of 2010
- **East and West Coast processing locations through PCT**

Adult stem cell R&D

- **Global R&D HQ – Cambridge, MA**
  - Advanced equipment & talented research team
- **VSEL™ technology (very small embryonic-like stem cells)**

Proprietary Patent and Patent Applications

Collection Process

- Low-dose, short course, cytokine induction of stem cell mobilization
- Collection of adult stem cells from peripheral blood of healthy individuals for future use
- Process for preparation and storage of collected stem cells
- Multiple storage vials

Cell Type

- Identification, isolation, and use of very small embryonic-like stem cells
- Therapeutic treatment of diseases with very small embryonic-like stem cells

Cosmetic Surgery

Delivery Technology

- Cutaneous wound healing with fibrin

Before

After

- Age-related tissue loss in face or other selected areas with growth factor
- Percutaneous administration of stem cells for cartilage and disc repairs

Non-closing fracture

2 months post-BMSC



Progressive Stem Cell Environment in China

- Leverage platform to begin launching stem cell therapies in China in 2010
  - Different clinical/regulatory pathway vs. U.S. – MoH instead of SFDA
  - More receptive of advanced therapeutics such as stem cell therapy
  - Broader consumer acceptance of non-traditional therapies
  - Favorable medical tourism trend
  - Government – healthcare reform, innovative technologies/therapies
- Transfer knowledge and data to accelerate U.S. stem cell therapy development cost effectively

Executing China Stem Cell Operations

2009 Milestones

- Established legal framework to commence operations in China
- Collaboration agreements with local partners
  - Wendeng Hospital
  - Qingdao Second Sanatorium
  - Enhance Biomedical Holdings
- Licensed space for stem cell R&D and processing facility in Beijing
- Acquired stem cell therapeutic delivery mechanisms

2010 Targets

- Complete collaborative partnership for stem cell banking business
- Launch 1st stem cell therapeutic procedure in orthopedics in PRC
- Create 1st anti-aging therapeutic program in PRC
- Open 1st anti-aging & cosmetic treatment center in Taiwan
- Initiate construction of Beijing stem cell facility
- Build additional collaborative relationships for future launches

Cord Blood Stem Cell Banking Companies

- China Cord Blood (NYSE: CO)
  - Acquired by Pantheon China Acquisition Corp. in June 2009
  - 9/30/09 LTM revenue = $34.3 million
  - Current enterprise value = ~$350 million (10.2x LTM revenue)

- ViaCell, Inc.
  - Acquired by PerkinElmer, Inc. in October 2007
  - Transaction size = ~$300 million (5.1x LTM revenue at acquisition)
  - Premium of ~36% over market cap prior to announcement

Source: Capital IQ

Stem Cell Therapeutic Companies

	Cytori	Geron
Stem Cell Source	Adult (Autologous) Mesenchymal	Embryonic
Targeted Segments	System for Collection	Therapeutics
Targeted Geographies	U.S. Europe	U.S.
Other Pharmaceuticals	None	Cancer (Phase II)
LTM Revenue	$14 million	$2 million
Approximate Enterprise Value	> $300 million	> $400 million

Sources: Capital IQ and company websites

Pharmaceuticals – China

Large Chinese Pharmaceutical Opportunity

- **China announced $124 billion budget to improve healthcare system in 2009-11**
  - Provide universal medical service to China's 1.3 billion population
  - New Rural & Urban Cooperative Medical Insurance System – at least 90% of population will be covered by 2011
  - Construction of 30,000 new hospitals, clinics and healthcare centers
- **Pharmaceutical market forecasted to reach $78 billion by 2013**
  - China to become third largest drug market (behind U.S. and Japan)
- **Antibiotics market $8+ billion in 2007**
  - 24% annual average growth rate for previous three years
  - Many antibiotics will be covered as "essential medicines" under the new healthcare insurance system giving end users 100% payment coverage

Erye – Profitable & Growing

- Vertically-integrated manufacturer of generic antibiotic Rx products and APIs
  - 7 cGMP-certified production lines
- Extensive distribution network covering all of PRC
  - No significant customer concentration
- 60% of current drug portfolio covered by insurance (expected to grow)
- Revenue has nearly doubled since 2007



Erye – Diversified Product Portfolio

No single drug accounting for >10% of sales

Top Ten Drugs in 2009 (52.6% of Total Sales)	
Drugs	% of Sales
Acetylspiramycin	7.5%
Oxacillin Sodium	7.2%
Mezlocillin Sodium for injection	6.9%
Amoxicillin Sodium & Sulbactam Sodium for injection	6.5%
Cefoperazone Sodium & Sulbactam Sodium for injection	5.2%
Amoxicillin & Potassium Clavulanate for injection	4.6%
Furbencillin Sodium for injection	4.0%
Ceftizozime Sodium for injection	3.9%
Ampivillin Sodium & Sulbactam Sodium for injection	3.7%
Azlocillin Sodium for injection	3.1%

Erye - Significant Capacity Expansion

- New facility completed in 2009
  - Penicillin sterile API facility for solvent crystallization and freeze dried raw material drugs with two cGMP lines approved
- 2010 / 2011 targets
  - Penicillin powder for injection facility
  - Cephalosporin powder for injection facility
  - Oral API facility
  - Freeze dried powder for injection facility
  - Capsule facility
  - Sterile cephalosporin API facility
- Future
  - Additional buildings available for expansion

Erye – Platform to Drive Growth

- **Current pipeline of 7 Rx drugs – one approved, three pending SFDA approval**
- **Growth strategy**
  - **Enhance R & D activities in China and the U.S.**
  - **In-license drugs with proven efficacy & efficacy that leverages new facility**
  - **Expand indications beyond anti-infectives**

Pipeline Drugs	Form/Dosage	Indication	Status
Omeprazole	Capsules (20mg)	GERD	Approved – Pending Launch
Cloxacillin sodium	Sterile API	Anti-infective	Pending SFDA Review
Clindamycin phosphate	Injection (0.3, 0.6G)	Antibiotic	Pending SFDA Review
Adefovir	API & Capsules (10mg)	Hepatitis B / HIV	Pending SFDA Review
Faropenem sodium	API	Anti-infective	In Clinical Trials
Faropenem sodium	Tablet (0.1G)	Anti-infective	In Clinical Trials
Tiopronin Enteric-Coated	Capsules (0.1G)	Hepatitis B	In Clinical Trials

Chinese Pharmaceutical Companies

($ in millions, except per share data and multiples)

Company Name	Ticker	Price 1/29/10	EV	LTM Rev	LTM EPS	EV/ LTM Rev	Trailing P/ E
3SBio	SSRX	$11.44	139.1	44.3	0.46	3.1x	24.6x
China Biologic Products	CBPO	$9.91	229.0	94.5	0.38	2.4x	26.0x
China Pharma Holdings	CPHI	$3.48	147.1	57.5	0.48	2.6x	7.2x
China Sky One Medical	CSKI	$17.68	238.3	126.2	2.19	1.9x	8.1x
Sinovac Biotech	SVA	$6.00	300.1	60.2	0.32	5.0x	18.8x
Tianyin Pharma.	TPI	$3.58	80.0	46.7	0.33	1.7x	11.0x
Mean						**2.8x**	**15.9x**
Median						**2.5x**	**14.9x**

Source: Capital IQ

Financials

Historical Income Statement

($ in 000s)	NBS		CBH / Erye	
	LTM 9/30/09	LTM 9/30/08	LTM 9/30/09	LTM 9/30/08
Revenues	192	207	58,001	46,147
Gross Profit	80	179	19,303	13,523
Gross Margin %	*NM*	*NM*	*33.3%*	*29.3%*
Operating Inc. (Loss)	(16,175)[1]	(9,142)	12,213	7,647
Operating Margin %	*NA*	*NA*	*21.1%*	*16.6%*
Net Inc. (Loss) before Minority Int.	NA	NA	9,525	6,040
Minority Interest Expense	NA	NA	5,487	3,556
Net Inc. (Loss)	(16,209)[1]	(9,154)	4,038	2,484

Source: Company filings
[1] Includes $6.4 million related to the acquisition of CBH and the expansion into China.

Pro Forma Balance Sheet

Pro Forma Balance Sheet[1] ($ in 000s)	9/30/09
Cash & Short-term Investments	8,711
Total Assets	85,064
Current Liabilities	20,875
Long-term Liabilities	7,703
Total Liabilities	28,578
Total Equity	47,287

Source: Company filings
[1] Pro forma for October 2009 acquisition of China Biopharmaceutical Holdings and its 51% ownership in Erye.

Ownership & Equity Data (as of 2/18/10)

Ownership (post-offering)	% Outstanding	% Based on SEC Beneficial Ownership
Management & Directors (Excluding RimAsia)	4.8%	10.5%
EET / Fullbright (Erye Managers and Minority Interest Holder)	8.0%	10.2%
RimAsia	28.7%	46.3%
Enhance Biomedical Holdings (Strategic Partner)	9.3%	17.0%
Public / Other	49.2%	58.6%

Capitalization (Common Share Equivalent in 000s)	Shares Outstanding	% Outstanding
Convertible Redeemable Series B & C Preferred stock	9,096	11.3%
Common Stock	42,946	53.3%
Total Warrants; Average Exercise Price $2.69	18,436	22.9%
Total Options; Average Exercise Price $1.94	10,066	12.5%
Fully-diluted Shares Outstanding	80,543	100.0%

Source: Company filings

Management and Boards

Key Executives

Robin Smith, MD MBA CEO & Chairman of the Board	▪ MD – Yale; MBA – Wharton ▪ Formerly President & CEO IP2M (HC multimedia), EVP & CMO HealthHelp (radiology management) ▪ Trustee of NYU Medical Center; Chairman of the Board of NYU Hospital for Joint Diseases (through November 2009) and Stem for Life Foundation
Jian Zhang General Manager, Suzhou Erye	▪ Joined Erye in 2003; extensive experience in the Chinese pharmaceutical industry ▪ Degree in Finance and Accounting from Central Television University ▪ Certified Public Accountant in China
Peter Sun, MD General Manager, NeoStem (China)	▪ Masters in Biotechnology & Pharmacology – University of British Columbia ▪ Licensed, endocrinologist; ~20 years of experience in pharmaceutical, biotech & medical ▪ Formerly with Sun Biomedical Labs; Panagin Pharma
Larry May Chief Financial Officer	▪ BS Business Administration – University of Missouri ▪ Formerly Treasurer & Controller at Amgen; SVP Finance & CFO at BioSource Intl ▪ Extensive experience building accounting, finance and IT operations
Catherine Vaczy, Esq VP and General Counsel	▪ BA – Boston College; JD – St. John's University ▪ Formerly VP of Legal and Associate General Counsel for Imclone Systems Inc. ▪ Formerly Corporate Counsel at Ross & Hardies, New York Office, Life Science Practice ▪ Member of the Board of Stem for Life Foundation
Alan Harris, MD PhD FACP FRCP VP of Drug Development and Regulatory Affairs	▪ MD – University of Strasbourg (France); PhD – Erasmus University (Netherlands) ▪ Currently Adjunct Prof of Pharmacology NYU Medical School; Formerly Assoc Prof of Medicine UCLA School of Medicine, Dir of Clinical Pharmacology Cedars-Sinai Medical Center ▪ Formerly with NPS Pharmaceuticals; Pfizer; Schering-Plough; Novartis

Board of Directors

Robin Smith, MD, MBA **CEO and Chairman**	▪ See Key Executives
Eric Wei **Managing Partner, RimAsia Capital Partners**	▪ BS Mathematics & Economics – Amherst College; MBA – Wharton ▪ Experience – Founder/Managing Partner of RimAsia Capital Partners (private equity); Peregrine Capital, Prudential Securities, Lazard Freres, Citibank; Gilbert Global Equity PartnersCrimson Asia Capital Partners
Mingsheng Shi, Chairman of the Board of Suzhou Erye Pharmaceutical	▪ Joined NeoStem Board of Directors in March 2010 ▪ BSc Economics & Management – Party School of the Communist Party of China ▪ Professional title of Senior Economist ▪ Extensive experience in pharmaceutical industry in China
Steven Myers (Independent)	▪ BS Mathematics – Stanford University ▪ Experience – Founder/Chairman/CEO SM&A (competition management services); career in aerospace and defense sectors supporting DoD & NASA programs
Drew Bernstein, CPA (Independent)	▪ BS – University of Maryland Business School ▪ Licensed in State of New York; member AICPA, NYSSCPA and NSA ▪ Experience – Bernstein & Pinchuk LLP (member of BDO Seidman Alliance); PRC auditing; 200+ real estate transactions with $3B+ aggregate value; accountant and business advisor
Richard Berman (Independent)	▪ Over 35 years of venture capital, management, M&A experience ▪ Experience – Current Board of Directors of NexMed, Easylink Services International, Inc., Advaxis, Inc., Broadcaster, Inc., National Investment Managers
Edward Geehr, MD (Independent)	▪ BS – Yale University; MD – Duke University ▪ Experience – Abraxis Bio-Science; Allez Spine; IPC-The Hospitalist Company

Scientific Advisory Board

Wayne Marasco, MD, PhD (Chairman)	▪ Associate Professor, Dept of Cancer and Immunology & AIDS at Dana-Farber Cancer Institute; Associate Professor of Medicine at Harvard Medical School ▪ Leading NeoStem's independent research efforts and collaborations
Douglas Losordo, MD (ACC, ADA, ASGCT)	▪ Director of the Feinberg Cardiovascular Research Institute at Northwestern's Feinberg School of Medicine ▪ Associate Editor of *Circulation Research* and serves on the editorial boards of *Circulation*, *Vascular Medicine*, and *Stem Cells*, among others.
Vincent Falanga, MD	▪ Professor of Dermatology and Biochemistry at Boston University ▪ Chairman of Dermatology at Roger Williams Medical Center (RI)
Ron Rothenberg, MD (FACEP)	▪ MD – Columbia University ▪ Founder of California Health Span Institute; Attending Physician at Scripps Memorial Hospital; previously Clinical Professor at UCSD School of Medicine ▪ 10th M.D. in the world to be fully board certified by American Board of Anti-Aging Medicine
Mariusz Ratajczak, MD, PhD	▪ World renowned investigator in adult stem cell and co-inventor of NeoStem's exclusively licensed VSEL™ technology ▪ Director of Stem Cell Institute at James Graham Brown Cancer Center; Professor in Department of Microbiology and Immunology – University of Louisville
Richard Gatti, MD	▪ Professor at UCLA; Pathologist at UCLA Medical Center ▪ Early pioneer of bone marrow transplantation; leading authority in gene therapeutics ▪ Co-authored hundreds of papers on molecular ID/treatment of genetic disorders
Vincent Giampapa, MD	▪ Board Certified Plastic Reconstructive Surgeon and Assistant Clinical Professor of Plastic and Reconstructive Surgery at University of Medicine and Dentistry of NJ ▪ Director of Plastic Surgery Center Intl; The Giampapa Institute for Anti-Aging Medical Therapy

Contact Information

NeoStem, Inc.

Robin Smith, MD, MBA
Chairman & CEO
Phone: (212) 584-4174
Email: rsmith@neostem.com
http://www.neostem.com

CCG Investor Relations, Inc.

Lei Huang
Account Manager
Phone: (646) 833-3417 (New York)
Email: lei.huang@ccgir.com
http://www.ccgir.com

Crocker Coulson
President
Phone: (646) 213-1915 (New York)
Email: crocker.coulson@ccgir.com


Thank You
NEOSTEM, INC. (“NBS”)
Investor Presentation
NeoStem
YOUR CELLS • YOUR USE • YOUR LIFE
WWW.NEOSTEM.COM

Appendix

Stem Cell Wound Healing – Case Study #1

Use of autologous bone marrow-derived cultured cells to treat chronic wounds (cells delivered under a film dressing; *Arch Dermatol, JAMA publication, 2003*)



Stem Cell Wound Healing – Case Study #2

A) Non-healing leg ulcer



B) During 3rd application of stem cells



C) Healing during treatment



D) Complete closure after 6 months – minimal scarring



Stem Cell Wound Healing – Case Study #3

A) Double barreled syringe to spray stem cells

B) Large wound on the back after surgery to remove a skin cancer



C) Spraying stem cells into the wound



D) Wound completely healed after 7 weeks



Size-based Separation of Apheresis Product by Elutra

Fraction 1 – Platelets and Serum

Fraction 2 – Cells smaller than RBC, enriched in very small embryonic-like stem cells

Fraction 3 – Some RBC and other cells

Fraction 4 – Most of the RBCs

Fraction 5 – 80-90% of the Total Nucleated Cells

Size-based Separation of Apheresis Product by Elutra (Cont.)



VSEL™ Technology can be enriched by size-based separation (Elutriation) of various cell fractions in the Apheresis product (n=3)

- Fraction 1 (Flow rate 20 mL/min)
- Fraction 2 (50 mL/min), highly enriched in very small embryonic-like stem cells and can be used to harvest purified populations of very small embryonic-like stem cell for clinical applications
- Fraction 3 (70 mL/min)
- Fraction 4 (90 mL/min)
- Fraction 5 (>90 mL/min)

Erye – Drug Approval Track Record

Year	Description	Dosage	Approval Date
2007	amoxicillin sodium & sulbactam sodium for injection	0.375g	05/20/07
	piperacillin sodium & tazobactam sodium for injection	1.125g	04/18/07
	piperacillin sodium & tazobactam sodium for injection	2.25g	04/18/07
	piperacillin sodium & tazobactam sodium for injection	3.375g	04/18/07
	piperacillin sodium & tazobactam sodium for injection	4.5g	04/18/07
	cefminox sodium for injection	0.5g	11/09/07
	cefminox sodium for injection	1.0g	11/09/07
2008	Ozagrel for injection	80mg	03/11/08
	sulbenicillin sodium	raw material	03/18/08
	Azithromycin capsules	0.25g	05/08/08
	Vecuronium Bromide	raw material	09/22/08
2009	piperacillin sodium & sulbactam sodium for injection	1.5g	01/09/09
	piperacillin sodium & sulbactam sodium for injection	3.0g	01/09/09
	Diammonium Glycyrrhizinate capsules	50mg	04/05/09
	Omeprazole Enteric-coated Capsules	20mg	12/15/09

Patent and Patent Application Details

	Patent/Application Titles	Country	Patent/Application Numbers	Date Filed
Collection Process	"Elective Collection and Banking of Autologous Peripheral Blood Stem Cells."	US	11/396,238	03/30/06
		Canadian	2548580	04/05/04
	"Processing Procedure for Peripheral Blood Stem Cells."	US	11/763,655	06/15/07
		European	07809600.95	06/15/07
		Chinese	200780030328.6	06/15/07
	"Mesenchymal Stem Cells Isolated from Mobilized Peripheral Blood"	US	61/266,825	12/04/09
	"Method of Isolation of Stem Cell Populations from Peripheral Blood Using Size-Based Separation"	US	61/266,860	12/04/09
VSEL™ Technology	"Very Small Embryonic-Like Stem Cells and Methods of Isolating and Using the Same."	US	12/096,754	11/02/06
		US	12/261,958	10/30/08
		European	06827358.0	11/02/06
		Chinese	200680052508.X	11/02/06
	"Transplantation of Very Small Embryonic-Like Stem Cells for Cardiac Repair Following Myocardial Infarction."	US	PCT/US2008/081832	10/30/08
	"Methods for Isolating Very Small Embryonic-Like Stem Cells from Cord Blood."	US	PCT/US2009/005414	09/30/09
Wound Healing	"Autologous Bone Marrow-Derived Cultured Mesenchymal Stem Cells Delivered in a Fibrin Spray Accelerate Healing in Murine and Human Cutaneous Wounds"	US	61/039,941	03/27/07
		US	12/413,250	03/27/09
		US	PCT/US2009/038666	03/27/09
Tissue Restoration	"Method and Compositions for Restoration of Age Related Tissue Loss in the Face or Selected Areas of the Body."	*US*	*Patent no 7414021 issued on 8/19/08*	
		US	12/218,334	07/14/08
	"Method and Composition for Restoration of Age Related Tissue Loss in the Face or Selected Areas of the Body."	US	61/175,275	05/04/09
Bone and Cartilage Repair	"Mesenchymal Stem Cell Isolation and Transplantation Method and System to be Used in a Clinical Setting."	US	60/761,441	01/24/06
		US	PCT/US2007/60889	01/23/07
		European	07762515.0	01/23/07
		Hong Kong	09103392.9	01/23/07
		Canadian	2640185	01/23/07
		US	12/161,911	11/07/08
	"Methods and Compositions for Optimized Expansion and Implantation of Mesenchymal Stem Cells."	US	11/773,774	07/05/07
		US	PCT/US2008/68202	06/25/08
	"Compositions to Promote Implantation and Engraftment of Stem Cells."	US	61/014,987	12/19/07
		US	PCT/US2008/87452	12/18/08
	"Compositions and Methods for Cartilage Repair."	US	61/036,551	03/14/08
		US	PCT/US2009/037126	03/13/09
	"Methods and Compositions for Intervertabral Disc Repair."	US	61/120,098	12/05/08
		US	61/154,874	02/24/09